Wave Life Sciences grants Mark Corrigan stock awards

The option covers 64,000 common shares at a $3.75 exercise price and expires October 5, 2036.

Rhea-AI Filing Summary

Wave Life Sciences, Inc. director Mark Corrigan acquired 10,700 restricted stock units and an option covering 64,000 common shares on October 5, 2026, under the 2026 Non-Employee Director Compensation Policy. Both awards vest in full on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027. The option has a $3.75 per-share exercise price and expires October 5, 2036. After the awards, his reported common-stock position was 39,515 shares and his option position covered 64,000 shares.

Insider Trade Summary

Grant/Award: 74,700 shares

Grant/Award 2 txns

Insider CORRIGAN MARK

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F2	64,000	$0.00	$0.00
Grant/Award	Common Stock F1	10,700	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 64,000 contracts (Direct); Common Stock — 39,515 shares (Direct)

Footnotes (2)

1. F1. The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.
2. F2. The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

Key Figures

Restricted stock units awarded: 10,700 units Shares covered by option: 64,000 shares Option exercise price: $3.75 per share +3 more

6 metrics

Restricted stock units awarded 10,700 units Awarded October 5, 2026

Shares covered by option 64,000 shares Option awarded October 5, 2026; reported option position following the transaction

Option exercise price $3.75 per share Option covering common shares

Common shares following RSU award 39,515 shares Reported after the October 5, 2026 award

Award vesting 100% Both awards vest on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027

Option expiration October 5, 2036 Option covering common shares

Key Terms

restricted stock unit award (RSU), vesting, exercise price, Non-Employee Director Compensation Policy

4 terms

restricted stock unit award (RSU) financial

"granted this restricted stock unit award (RSU)"

vesting financial

"The RSU vests as to 100% of the shares"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

exercise price financial

"the option's $3.75 per-share exercise price"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

Non-Employee Director Compensation Policy financial

"pursuant to the 2026 Non-Employee Director Compensation Policy"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What awards did WVE director Mark Corrigan receive?

Wave Life Sciences, Inc. director Mark Corrigan received 10,700 restricted stock units and an option covering 64,000 common shares on October 5, 2026. The awards were granted under the 2026 Non-Employee Director Compensation Policy.

When do Mark Corrigan's WVE awards vest, and what is the option exercise price?

The option's exercise price is $3.75 per share. Both awards vest as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027; the option expires October 5, 2036.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/07/2026 - 09:00 PM Accepted by SEC EDGAR 10/07/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

CORRIGAN MARK

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES, INC.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences, Inc. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	10/05/2026		A		10,700(1)	A	$0	39,515	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$3.75	10/05/2026		A		64,000		(2)	10/05/2036	Common Stock	64,000	$0.00	64,000	D

Explanation of Responses:

1. The reporting person was granted this restricted stock unit award (RSU) pursuant to the 2026 Non-Employee Director Compensation Policy. The RSU vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

2. The reporting person was granted this option pursuant to the 2026 Non-Employee Director Compensation Policy. The option vests as to 100% of the shares on the earlier of the Company's 2027 annual meeting of stockholders or October 5, 2027.

Remarks:

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney

	/s/ Mark Corrigan	10/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)